Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Vasculitis is considered to be secondary when it arises either in the context of a pre-existing connective tissue disease, as a result of direct infection with a limited range of organisms, especially viruses, or when it arises in response to exposure to a number of medications. Rheumatoid vasculitis is probably the most widely recognised form of secondary vasculitis, and in this article we review the incidence, clinical features and management of this condition. Infections may either trigger or cause some types of vasculitis. Drug therapy is a common cause of limited forms of vasculitis and may enhance our understanding of the mechanism of these diseases. The premature development of atherosclerosis in patients with existing connective tissue diseases or indeed primary vasculitis has been recognised for some time, and the underlying mechanisms are currently being studied. An appreciation of the complex and varied pathophysiology of secondary vasculitis may further our understanding of primary vasculitis.

Type

Journal article

Journal

Best practice & research. Clinical rheumatology

Publication Date

04/2005

Volume

19

Pages

321 - 336

Addresses

Department of Rheumatology, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK. raashid.luqmani@ed.ac.uk

Keywords

Humans, Vasculitis, Connective Tissue Diseases, Immunosuppressive Agents, Antibodies, Antineutrophil Cytoplasmic, Glucocorticoids, Treatment Outcome, Clinical Trials as Topic